Biomarkers of desensitization / tolerance in food allergy AIT

Carmen Riggioni MD, MSc, PhD student JM EAACI Immunotherapy Group



Disclosure

In relation to this presentation, I declare no real or perceived conflicts of interest

Funding


- EAACI research fellowship
- SEICAP grant

A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation.

Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (e.g. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.



Biomarkers in FA-AIT



Shamji, Allergy Clin Immunol 2017;140:1485-98

Importance of Biomarkers

- Distinguish patients with the highest likelihood of responding to AIT.
- Guidance regarding when to discontinue AIT.
- Predicting symptomatic relapse or adverse events.
- Stratify the patient in a protocol that they can realistically follow.
- The type of maintenance the patient should undertake.

Definitions:

Desensitization

• Effectiveness during treatment

• The ability to safely consume foods containing the culprit allergen while on allergen immunotherapy.


Tolerance

•Sustained unresponsiveness.

Post-discontinuation effectiveness


•The ability to safely consume a normal serving of food containing the trigger allergen despite a period of absence of exposure

Novel Baseline Predictors of Allergic Side Effects During Peanut Oral Immunotherapy



J Allergy Clin Immunol. 2017 March ; 139(3): 882–888.e5


- 80% presented adverse events
 - 72% build-up
 - 47% maintenance
- 42% experienced systemic reactions
 - Predictors: baseline allergic rhinitis, asthma
 - 2.9-fold higher
- 49% experienced gastrointestinal symptoms
 - Peanut SPT predicted increased gastrointestinal sx
 - 1.4-fold for every 5 mm
- 20% of subjects dropped out, half due to persistent gastrointestinal symptoms




• Ovomucoid 8.85 kU/L

Vazquez-Ortiz et al. Baseline specific IgE levels are useful to predict safety of oral immunotherapy in egg-allergic children. Experimental Allergy, 2014 (44) 130–141.

CM IgE ≥50 kU/L **CM-SPT** ≥9mm Anaphylaxis OFC



Vazquez-Ortiz et al. Safety and predictors of adverse events during oral immunotherapy for milk allergy: severity of reaction at oral challenge, specific IgE and prick test. Clinical & Experimental Allergy, 2013 (43) 92–102.



J Allergy Clin Immunol. 2016 April ; 137(4): 1103–10.e1-11.

Characteristics at baseline of successful patients

- Smaller baseline SPT to milk (p=0.012)
- Smaller baseline end point titration SPT to milk (p=0.11)
- Lower median milk-specific IgE
- Log₁₀ casein-specific lgE (p=0.012)
- Greater baseline casein-specific IgG4/IgE ratio (p=0.007)
- No change in BAT


J Allergy Clin Immunol. 2016 April ; 137(4): 1103–10.e1-11.

Sustained unresponsiveness

- The addition of omalizumab to OIT markedly improves safety with no significant effects on efficacy.
- With or without omalizumab, most subjects could be desensitized to a high dose (10g) of milk protein over a 24 month period, but half had increased reactivity after an 8 week period of avoidance.

Mechanistic correlates of clinical responses to OMZ in the setting of CM-OIT

- Investigate mechanisms by which OMZ modulates immunity in the context of OIT to identify baseline biomarkers.
- Pre-OIT basophil reactivity positively associated with occurrence of symptoms during OIT.
- Baseline milk IgE/total IgE ratio correlated with the likelihood of achieving sustained unresponsiveness.
- Combining omalizumab therapy with milk OIT led to distinct alterations in basophil reactivity but not T-cell responses.



J Allergy Clin Immunol 2017;140:1043-53.


Treg biomarkers might be useful in predicting immune tolerance in peanut OIT


- 23 peanut-allergic patients underwent peanut OIT vs. 20 peanut-allergic controls.
- Antibody and basophil activation measurements did not statistically differentiate between peanut OIT and controls.
- T-cell function and demethylation of *FOXP3* CpG sites in antigen-induced Treg were significantly different between tolerant and non-tolerant participants.
- Modifications at the DNA level of antigen-induced T-cell subsets may be predictive of sustained unresponsiveness during peanut OIT.

J Allergy Clin Immunol. 2014 February ; 133(2): 500–510

The number and types of epitopes bound by patients' IgE and IgG4 antibodies associated with:

- Type of adverse events in OIT
- Efficacy of OIT





Comparison of the two patient groups:


- Children who discontinued CM-OIT due to adverse reactions (red, n=6)
- Children who successfully completed OIT (blue, n=26)

COMPLETED OIT

- IgE binding decreased and IgG4 binding increased significantly from the initiation to completion of OIT.
- Had IgE and IgG4 antibodies that more often recognized the same epitopes.

DISCONTINUED OIT


 Had IgE and IgG4 antibodies that bound to CM peptides with greater intensity, broader diversity and greater affinity.



- In children with high IgE binding to CM epitopes, lower antibody affinity may discriminate those who will complete OIT successfully from those who will have to discontinue therapy.
- Combining measurements of IgE and IgG4 binding intensity and affinity to the CM epitopes distinguishes the two patient groups better than any single traditional parameter.

Innate Lymphoid Cells

 Specific studies targeting ILC2 response during immunotherapy for food allergy is presently lacking, with additional studies needed to evaluate its use in predicting clinical outcome.



Can biomarkers replace OFC ?

- The standard of assessing long term efficacy is through OFC
- Reliable biomarkers could help eliminate the need for OFC and provide a safer and more convenient alternative to these challenges.

REALITY :

- FEW AND NOT PERFECT ALTERNATIVES
- WEAK TRANSLATION TO CLINICAL PRACTICE

TAKE HOME MESSAGES

- There are no ideal biomarkers that can determine tolerance and desensitization to date.
- More homogeneity in FA-AIT trials is needed to come up with useful and robust clinical tools.
- It is important to consider each patients' individual profile before starting FA-AIT, plus the families' commitment and adherence.
- Set realistic goals for your patient and their families prioritizing, safety and education.
- Remember FA-AIT is a long term commitment for both families and physicians and should be monitored accordingly.